Engineered Phages and Engineered and Recombinant Endolysins Against Carbapenem‐Resistant Gram‐Negative Bacteria: A Focused Review on Novel Antibacterial Strategies
Journal of Basic Microbiology · 2025
DOI: 10.1002/jobm.70078 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Basic Microbiology, 2025. Verfasst von Majid Taati Moghadam und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran. Hauptthemen laut MEDLINE: Bacteriophages, Anti-Bacterial Agents, Gram-Negative Bacteria, Endopeptidases. Die Arbeit nennt 159 Literaturangaben.
Abstract (Originalsprache)
Antibiotic resistance has escalated globally, affecting not only commonly used antibiotics but also last‐resort agents such as carbapenems and colistin. The rise of antibiotic‐resistant bacteria has prompted microbiologists to devise new strategies, with bacteriophages emerging as one of the most promising options. Nevertheless, certain mechanisms have been identified in bacteria that confer resistance to phages. While phage resistance is currently less widespread than antibiotic resistance, challenges such as biofilm formation, newly emerging resistance mechanisms against phages, and the natural limitations of unmodified phages have driven the advancement of engineered phages. This study aims to examine the efficacy of engineered phages and both engineered and recombinant endolysins against carbapenem‐resistant Gram‐negative bacteria (CR‐GNB). We performed a literature review through PubMed, Scopus, Web of Science, and Google Scholar, concentrating on studies that utilized these agents against carbapenem‐resistant Gram‐negative bacteria (CR‐GNB). Reviewed studies indicate potential antibacterial activity of these agents against CR‐GNB. By engineering and modifying phages, these agents exhibit improved antimicrobial efficacy, temperature stability, and membrane permeability. Furthermore, they demonstrate the ability to eliminate bacteria with multidrug‐resistant (MDR) and extensively drug‐resistant (XDR) profiles. These findings suggest the promising potential of engineered phages and endolysins for future clinical applications against CR‐GNB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
- Department of Microbiology, Faculty of Basic Sciences, North Tehran Branch, Islamic Azad University, Tehran, Iran.
- Nanotechnology and Advanced Research Center, University of Technology-Iraq, Baghdad, Iraq.
- Department of Genetics, Islamic Azad University - Tonekabon Branch, Mazandaran, Iran.
- Department of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
- Department of Medical Biotechnology, School of Allied Medical Sciences, Iran University of Medical Sciences (IUMS), Tehran, Iran.
ORCID-Profile: Majid Taati Moghadam, Samira Sabzi, Shahla Shahbazi
Zitieren
APA
Moghadam, M. T., Shahkolahi, S., Hashim, I. A., Asgharihajimahalleh, S., Khodadadi, G., Moghbeli, F., Sabzi, S., & Shahbazi, S. (2025). Engineered Phages and Engineered and Recombinant Endolysins Against Carbapenem‐Resistant Gram‐Negative Bacteria: A Focused Review on Novel Antibacterial Strategies. Journal of Basic Microbiology. https://doi.org/10.1002/jobm.70078
Vancouver
Moghadam MT, Shahkolahi S, Hashim IA, Asgharihajimahalleh S, Khodadadi G, Moghbeli F, et al. Engineered Phages and Engineered and Recombinant Endolysins Against Carbapenem‐Resistant Gram‐Negative Bacteria: A Focused Review on Novel Antibacterial Strategies. Journal of Basic Microbiology. 2025. doi:10.1002/jobm.70078
BibTeX
@article{Moghadam2025,
author = {Moghadam, Majid Taati and Shahkolahi, Shaghayegh and Hashim, Israa A and Asgharihajimahalleh, Shamsieh and Khodadadi, Ghazale and Moghbeli, Fatemeh and Sabzi, Samira and Shahbazi, Shahla},
title = {Engineered Phages and Engineered and Recombinant Endolysins Against Carbapenem‐Resistant Gram‐Negative Bacteria: A Focused Review on Novel Antibacterial Strategies},
journal = {Journal of Basic Microbiology},
year = {2025},
doi = {10.1002/jobm.70078}
}
EUVIMED